Corcept Therapeutics Incorporated (CORT)
CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up
Corcept stock jumps after the company announces plans to resubmit relacorilant's NDA for treating Cushing's syndrome.
Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade
The consensus price target hints at a 43.3% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?
Corcept raises 2026 revenue guidance after strong Korlym Q1 performance. New launches and pipeline progress may diversify future growth.
Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement
Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects further upside from European approval, additional oncology indications, and a triple-combo study with Avastin, with key data and decisions anticipated by year-end. Phase 2 data for dazucorilant in ALS showed significant 1- and 2-year survival benefits, supporting a planned phase 3 study targeting overall survival as a primary endpoint.
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
Corcept Therapeutics (CORT) came out with a quarterly loss of $0.3 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.17 per share a year ago.
Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade)
Corcept Therapeutics Incorporated receives early FDA approval for Lifyorli (relacorilant) in platinum-resistant ovarian cancer, transforming its investment narrative. Lifyorli demonstrated a 35% reduction in risk of death and strong tolerability, positioning CORT as a new oncology leader in ovarian cancer. Analyst consensus sees Lifyorli's growth offsetting Korlym's decline, with 2026 sales guidance at $900M–$1B and potential blockbuster expansion.
CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer
Corcept jumps after FDA approves Lifyorli combo for platinum-resistant ovarian cancer, marking the first-of-its-kind treatment.
Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead?
CORT's Korlym 2025 sales rises 13% Y/Y, with 2026 revenues seen at $900M-$1B. However, the court ruling favoring Teva's generic may put pressure on future sales.
Corcept's Q4 Earnings and Revenues Fall Short of Estimates
CORT misses Q4 earnings and revenue estimates despite 11% sales growth year over year.
Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.2 per share, missing the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.26 per share a year ago.
